A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 307 participants.
Also called NCT01760460
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 307 participants
- Sponsor
- Registry
-
NCT01760460
-
- Main results
- Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01760460. Randomized; double masking; primary purpose treatment. Start 2013-03-14 (actual); primary completion 2015-03-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)
- Condition
- Dyslipidemia
- Intervention (Drug)
- Anacetrapib
- Intervention (Drug)
- Placebo for anacetrapib
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01760460- Content hash
95a3e50a4c4f770b258cd6d43366a4f3171a32b613a9acee3040ebb35a047653